What it is
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, MW 1,419.54 Da, CAS 137525-51-0, PubChem CID 9941957) derived from a partial sequence of a protective protein found in human gastric juice. It was first isolated by Predrag Sikiric and colleagues at the University of Zagreb in 1993. Three consecutive proline residues at positions 3–5 give the molecule unusual stability — it remains intact in human gastric juice for over 24 hours and resists most peptidases (Sikiric 2024). This stability has enabled investigation of oral administration in animal models, distinguishing BPC-157 from most bioactive peptides that require parenteral delivery. Despite three decades of preclinical research, no major regulatory agency has approved it for human use.
In plain English
BPC-157 is a lab-made chain of 15 amino acids (the building blocks of proteins). It was copied from a small piece of a natural protein that protects the lining of the human stomach. A team at the University of Zagreb first isolated it in 1993. What is unusual about it: a string of three amino acids in the middle makes the whole molecule very stable — it can survive stomach acid for more than a day, while most peptides break down fast. That stability is why researchers have been able to test it by mouth in animal studies, instead of only by injection. Despite three decades of research, no major regulator has approved it for human use.
How it works
- 01
Modulation of the nitric oxide (NO) system
BPC-157 exerts vasoactive and cytoprotective effects through the nitric oxide system. Hsieh (2020, Scientific Reports) elucidated a Src–Caveolin-1–eNOS signaling cascade: BPC-157 phosphorylates Src kinase, which phosphorylates Cav-1, releasing eNOS from inhibitory binding and increasing NO production. Notably, the effect is bidirectional — BPC-157 counteracts both L-NAME-induced hypertension and L-arginine-induced hypotension, behaving as a homeostatic NO-system modulator rather than a pure agonist or antagonist.
In plain English
It acts like a thermostat for a blood-flow signal
Your body uses a signal called nitric oxide to tell blood vessels when to open or close. When they open, blood pressure drops. When they close, it rises. In animal studies, BPC-157 seems to keep this signal in balance. If the signal is too weak, it nudges it up. If it is too strong, it nudges it down. It acts more like a thermostat than an on-off switch.
- 02
VEGFR2 activation and angiogenesis
Hsieh (2017, J Mol Med) demonstrated that BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) at both mRNA and protein levels in endothelial cells, promotes VEGFR2 internalization (blocked by the endocytosis inhibitor dynasore), and activates the downstream Akt–eNOS cascade. This drives the consistent angiogenic effect observed at injury sites in animal models — and underlies BPC-157's interest in tissue repair, ischemia recovery, and collateral-vessel formation in vascular occlusion models.
In plain English
It helps grow new blood vessels where they're needed
When tissue gets hurt, your body grows new blood vessels to feed the repair. BPC-157 seems to turn up a switch on the outside of blood vessel cells that tells them to build more. More blood vessels bring more oxygen and more repair parts to the injury. In animal studies, this may be one reason wounds, strokes, and blocked arteries heal better.
- 03
FAK–paxillin pathway and tendon fibroblast migration
Chang (2011, J Appl Physiol) showed dose-dependent activation of focal adhesion kinase (FAK) and paxillin in tendon fibroblasts: enhanced expression and phosphorylation, increased fibroblast migration in transwell assays, F-actin cytoskeletal remodeling, and preserved viability under H₂O₂ oxidative stress. This is the proposed mechanism for the consistent tendon-healing effect in animal models. McGuire (2025) flags the same FAK-paxillin pathway as relevant in cancer cell biology — a theoretical safety question that remains untested in humans.
In plain English
It helps tendon cells move so tendons can rebuild
Tendons heal slowly because the repair cells inside them barely move around. In lab dishes, BPC-157 turned on two proteins that help those cells move, grow, and handle stress. That is likely why tendons heal faster in animal studies. One honest warning: those same two proteins are also busy in some cancer cells. No one has tested yet whether long-term use could help a tumor grow.
- 04
Growth hormone receptor upregulation
Lovric-Bencic (2018, Molecules) showed that BPC-157 increases growth hormone receptor (GHR) expression in tendon fibroblasts in a dose- and time-dependent manner, enhances GH sensitivity, and activates JAK2 phosphorylation. This provides a mechanism by which BPC-157 could amplify endogenous GH/IGF-1 axis signaling in damaged tissue without requiring exogenous GH administration.
In plain English
It makes tissues more responsive to your own growth hormone
Your body makes a natural signal called growth hormone that tells tissues to grow and repair. BPC-157 does not add more of that signal. Instead, it seems to add more catchers for the signal on tendon cells. That way, your own growth hormone works harder at the spot that needs it. More BPC-157 means more catchers — at least in lab dishes.
- 05
Cytoprotection and stress-response upregulation
Sikiric (2020, Gut and Liver) reviewed BPC-157's broader cytoprotective signature: upregulation of heat shock proteins (HSPs) and heme oxygenase-1 (HO-1), reduction of pro-inflammatory cytokines, mitochondrial preservation, and organoprotection extending across stomach, intestine, liver, pancreas, heart, and brain. Sikiric (2024, Pharmaceuticals) added neurotransmitter-system modulation — restoration of dopaminergic, serotonergic, GABAergic, and glutamatergic balance after experimental stress — which underlies the CNS-recovery findings (stroke, TBI, spinal cord injury) reviewed by Vukojevic (2022).
In plain English
It turns up the body's built-in cell protection
Your cells have built-in shield proteins that protect them from damage. BPC-157 turns up how many of those shields your cells make. In animal studies, this protection shows up in the stomach, gut, liver, pancreas, heart, and brain. It also seems to rebalance brain chemistry after stress. That may be why animals recover better from strokes, head injuries, and spinal cord injuries in the published research.
- 06
What is NOT known about the mechanism
No specific molecular receptor for BPC-157 has been identified. The pleiotropic effects across tissues are inferred from downstream pathway activation rather than receptor pharmacology. Pharmacokinetics in humans are essentially undocumented in peer-reviewed literature: animal data shows hepatic metabolism with a sub-30-minute plasma half-life and renal clearance, but human PK has not been formally characterized. This receptor-and-PK gap is a major reason the evidence grade is not higher despite the depth of mechanistic work.
In plain English
What we still don't know
No one has found the exact spot on a cell that BPC-157 latches onto. Every effect listed above was measured after that first step had already happened. The first step itself is still a mystery. We also don't know how the human body handles BPC-157 — how fast it clears, how much reaches tissues, or what the right dose is. In animals, it clears in under half an hour. In humans, that data is basically missing. Those two unknowns are the main reason the grade is not higher, even with all the animal research.